Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Tuberous Sclerosis 1Tourette Syndrome 1Tic Disorders 1Neurodevelopmental Disorders 1Fragile X Syndrome 1DiGeorge Syndrome 1Autistic Disorder 1Autism Spectrum Disorder 1Attention Deficit Disorder with Hyperactivity 1Anxiety Disorders 122q11 Deletion Syndrome 1

Interventions

pembrolizumab 219Carboplatin 218Specimen Handling 198Cisplatin 188Magnetic Resonance Spectroscopy 168Radiotherapy 152Bevacizumab 142Gemcitabine 135Cyclophosphamide 133Drug Therapy 118Capecitabine 118Paclitaxel 112Oxaliplatin 110Biopsy 107venetoclax 102Nivolumab 101Rituximab 83tislelizumab 81durvalumab 81toripalimab 77Fluorouracil 73Etoposide 72Dexamethasone 70sintilimab 67Radiosurgery 67Docetaxel 67Pemetrexed 65atezolizumab 64Azacitidine 63Injections 62

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Recruiting × Selective Serotonin Reuptake Inhibitors × Clear all
NCT06081348 2025-07-16

CALM

Holland Bloorview Kids Rehabilitation Hospital

Phase 2 Recruiting
130 enrolled

Autism Spectrum Disorder, Anxiety Disorders, Attention Deficit Disorder with Hyperactivity, Autistic Disorder, DiGeorge Syndrome, Fragile X Syndrome, Tourette Syndrome, Tic Disorders, Tuberous Sclerosis, 22q11 Deletion Syndrome, Neurodevelopmental Disorders

Data powered by HemOnc (CC BY 4.0) Colophon âš¡